U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. User Fee Waivers for FDC and Co-Packaged HIV Drugs for PEPFAR
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

User Fee Waivers for FDC and Co-Packaged HIV Drugs for PEPFAR February 2007

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-2005-D-0083
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This guidance describes the circumstances under which user fees will not be assessed under the Prescription Drug User Fee Act (PDUFA) for some applications for fixed dose combination (FDC) and co-packaged versions of previously approved antiretroviral therapies for the treatment of human immunodeficiency virus (HIV). The guidance also describes circumstances under which many of the applications, products, and establishments that will be assessed fees may be eligible for a public health or a barrier-to-innovation waiver. We expect that most of the applications, products, and establishments for FDC and co-packaged HIV therapies proposed for use in the President's Emergency Plan for AIDs Relief (PEPFAR) will either not be assessed fees in the first instance or will qualify for a waiver under the "other circumstances" part of the barrier-to-innovation user fee waiver. See the Attachment at the end of the guidance for a summary of available exemptions and waivers.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2005-D-0083.

 
Back to Top